We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-5.18%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.9B
AUM Growth
+$317M
Cap. Flow
-$92.4M
Cap. Flow %
-1.56%
Top 10 Hldgs %
47.94%
Holding
165
New
49
Increased
48
Reduced
28
Closed
27

Top Sells

Rank Stock Value
1
CPB icon
Campbell Soup
CPB
+$59.8M
2
LULU icon
lululemon athletica
LULU
+$56.9M
3
AMZN icon
Amazon
AMZN
+$46.6M
4
TH icon
Target Hospitality
TH
+$46.3M
5
ALKS icon
Alkermes
ALKS
+$43.6M

Sector Composition

Rank Sector Weight
1 Healthcare 44.61%
2 Consumer Discretionary 7.96%
3 Consumer Staples 6.71%
4 Communication Services 3.41%
5 Technology 2.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.2B 20.35%
28,000
+1,000
+4% +$441K
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$656M 11.12%
+30,000
New +$6.65M
INCY icon
3
Incyte
INCY
$23.5B
$163M 2.76%
2,372,000
+1,408,000
+146% +$107M
BMY icon
4
Bristol-Myers Squibb
BMY
$127B
$139M 2.36%
2,356,000
+678,000
+40% +$44.7M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$126M 2.13%
710,000
+50,000
+8% +$8.04M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$121B
$115M 1.95%
636,000
+36,000
+6% +$7.03M
TVTX icon
7
Travere Therapeutics
TVTX
$5.33B
$115M 1.95%
4,748,000
-1,000,000
-17% -$18.4M
BIIB icon
8
Biogen
BIIB
$29.9B
$105M 1.78%
372,000
+4,000
+1% +$1.31M
ENTA icon
9
Enanta Pharmaceuticals
ENTA
$372M
$104M 1.77%
1,836,000
-164,000
-8% -$8.11M
SUPN icon
10
Supernus Pharmaceuticals
SUPN
$2.68B
$104M 1.76%
3,900,000
+576,000
+17% +$15.5M
AVTX icon
11
Avalo Therapeutics
AVTX
$976M
$98.1M 1.66%
15,625
+2,049
+15% +$16.6M
PTCT icon
12
PTC Therapeutics
PTCT
$6.37B
$96.6M 1.64%
2,596,000
+504,000
+24% +$20.7M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$2.23B
$90M 1.52%
3,648,000
+276,000
+8% +$6.5M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.6B
$82.7M 1.4%
1,036,000
+444,000
+75% +$38.4M
ZYME icon
15
Zymeworks
ZYME
$1.68B
$73.3M 1.24%
2,524,000
+524,000
+26% +$17.4M
ALKS icon
16
Alkermes
ALKS
$8.82B
$72.7M 1.23%
2,356,000
-1,544,000
-40% -$43.6M
FIVE icon
17
Five Below
FIVE
$11.2B
$67.4M 1.14%
+381,266
New +$75.9M
ENR icon
18
Energizer
ENR
$1.44B
$64.4M 1.09%
1,648,000
+376,000
+30% +$15.1M
ARGX icon
19
argenx
ARGX
$57.4B
$62.8M 1.06%
208,000
+30,000
+17% +$9.51M
REGN icon
20
Regeneron Pharmaceuticals
REGN
$68.8B
$60.5M 1.03%
100,000
-56,000
-36% -$34.8M
BURL icon
21
Burlington
BURL
$22B
$60.4M 1.02%
212,994
-43,468
-17% -$13.9M
MDT icon
22
Medtronic
MDT
$107B
$56.4M 0.96%
450,000
-66,000
-13% -$8.54M
ASO icon
23
Academy Sports + Outdoors
ASO
$2.89B
$55.9M 0.95%
1,395,710
+470,384
+51% +$18.8M
CPRX
24
DELISTED
Catalyst Pharmaceutical
CPRX
$53M 0.9%
10,000,000
HAE icon
25
Haemonetics
HAE
$3.58B
$52.9M 0.9%
750,000
+126,000
+20% +$7.95M

Similar funds

Armistice Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Armistice Capital held 165 positions worth $5.9B, up 5.7% from $5.59B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital's Q3 2021 filing shows 49 new, 48 increased, 28 reduced and 27 closed positions. Its largest new stake was Five Below: 381,266 shares worth $67.4M. The largest sale was Campbell Soup, an estimated $59.8M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 44% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

  • Armistice Capital's largest Q3 2021 buy was Five Below: 381,266 shares worth $67.4M.
  • Armistice Capital added most to Incyte in Q3 2021, an estimated $107M increase.
  • Armistice Capital's biggest Q3 2021 reduction was Amazon, cutting an estimated $46.6M.
  • Armistice Capital fully exited Campbell Soup in Q3 2021, selling an estimated $59.8M.
  • Armistice Capital's ten largest holdings make up 48% of its $5.9B portfolio in Q3 2021.
  • Armistice Capital opened 49 new positions and closed 27 in Q3 2021.
  • Armistice Capital's portfolio value rose 5.7% quarter-over-quarter to $5.9B.

Based on Armistice Capital's 13F filing for Q3 2021, filed 15 Nov 2021.